• Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is expected to release its quarterly earnings with an estimated EPS of $10.56 and revenue of approximately $3.78 billion.
• The company's stock has seen a significant increase of over 16%, with a current P/E ratio of approximately 17.
• Regeneron's financial stability is highlighted by a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company known for its innovative medicines. The company focuses on developing drugs for serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, and infectious diseases. Regeneron competes with other pharmaceutical giants like Amgen and Biogen in the biotechnology sector.

Regeneron is set to release its quarterly earnings on January 30, 2026, with Wall Street analysts estimating an EPS of $10.56 and revenue of approximately $3.78 billion. The Zacks Consensus Estimate projects slightly higher revenues at $3.82 billion, with the same EPS of $10.56. Historically, Regeneron has exceeded earnings estimates in three of the last four quarters, with an average surprise of 21.81%.

The upcoming earnings report will focus on profits from the asthma drug Dupixent and sales of Eylea HD. While sales of the legacy Eylea have declined due to competitive pressures, the strong uptake of Eylea HD is expected to boost overall franchise revenues. The demand for Dupixent across multiple indications is likely to have driven solid profit growth, helping to offset the decline in Eylea sales.

Regeneron's stock has seen a significant increase of over 16% since the last analysis, reinforcing a Buy rating for REGN. Despite these recent gains, the stock is still trading below its all-time high of approximately $1,200, reached in August 2024. The earnings report could potentially drive the stock price higher if the results exceed expectations, while a miss might lead to a decline in the stock's value.

Regeneron has a price-to-earnings (P/E) ratio of approximately 17, indicating that investors are willing to pay $17 for every $1 of earnings. The company's price-to-sales ratio stands at about 5.44, and the enterprise value to sales ratio is roughly 5.46, indicating a consistent valuation metric. With a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06, Regeneron demonstrates a solid financial position.